China has tightened control over the production and sale of drugs in revisions made to an amendment of the Drug Administration Law. The measures were made public as the draft revisions are under review at the ongoing session of the Standing Committee of the National People's Congress.
The draft requires individuals and entities who have become medicine marketing authorization holders (MAHs) be responsible for the drugs' clinical and non-clinical trials, manufacturing, selling, and the analysis, report, and response of adverse reactions.
The MAHs should sign agreements with manufacturers, sellers, transporters, and keepers of the drugs to make sure they are capable of maintaining the quality of drugs and managing risks, the draft says.
[FULL STORY HERE]
World Politics News is dedicated to raising Americans' knowledge of political events, elections, and legislation throughout the world.
No comments:
Post a Comment